Trial Profile
The Comparative Study on Rh-Endostatin (Endostar) Continuous Intravenous Infusion and Routine i.v in Combination With GP Regimens for Phase III B/IV Squamous Cell Lung Cancer and Biological Markers Exploration.
Status:
Not yet recruiting
Phase of Trial:
Phase III
Latest Information Update: 20 Jan 2020
Price :
$35
*
At a glance
- Drugs Endostatin (Primary) ; Cisplatin; Gemcitabine
- Indications Lung cancer
- Focus Therapeutic Use
- Sponsors Simcere Pharmaceutical Group
- 10 Nov 2014 New trial record